



Xellia Pharmaceuticals Focuses on Innovation in Anti-infectives with Formation of Scientific Advisory Board

Brings together experts in infectious diseases, microbiology, respiratory medicine and pharmaceutical sciences

Copenhagen, Denmark – 17 December 2014 - Xellia Pharmaceuticals ('Xellia'), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today announces the formation of a new Scientific Advisory Board (SAB).

The SAB brings together leading international scientific and clinical advisors with expertise in infectious diseases, clinical microbiology, respiratory medicines and drug research and development. The SAB Chairman will be **Professor George E Griffin**, Emeritus Professor of Infectious Disease and Medicine at St George's, University of London, UK. Other members of the Board include:

- **Dr Andreas Rummelt**, a member of Xellia Board of Directors supporting R&D. Also CEO and Partner at InterPharmaLink AG, Basel, Switzerland.
- **Professor Gerhard Winter**, Department of Pharmacy, Ludwig Maximilian University of Munich, Munich, Germany.
- **Professor Christoph Tang**, The Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
- **Dr Tania Pressler**, Chief Attending Physician, Rigshospitalet, Copenhagen, Denmark.
- **Professor Keith S Kaye**, Division of Infectious Diseases and Department of Medicine at Wayne State University and Detroit Medical Center, Detroit, USA. He is also the Corporate Medical Director of Hospital Epidemiology and Antimicrobial Stewardship for both institutions.
- **Professor Anne O'Donnell**, Professor and Chief, Division of Pulmonary, Critical Care, and Sleep Medicine, Georgetown University Hospital, Washington DC, USA.
- **Professor Arjana Tambić Andrašević**, Head of the Department of Clinical Microbiology at the University Hospital for Infectious Diseases, Zagreb, Croatia.

Carl-Åke Carlsson, CEO, Xellia said: "As Xellia has continued to grow, the breadth of our science has increased beyond manufacturing of anti-infective generics to support more innovative product developments. We welcome the members of the new Scientific Advisory Board to the Company. Their scientific and clinical insight and guidance combined with our specialist expertise will help us improve the efficacy, increase safety profile and reduce the side effects of existing molecules and develop new drugs to help tackle the global crisis of antimicrobial resistance."

Professor George Griffin, Chairman of the SAB said: "Xellia has attracted an impressive Board of scientific and clinical advisors which I am proud to chair. Antimicrobial resistance is a huge area of unmet medical need and one of the greatest threats to human health. By working together, we can focus on overcoming

the challenges associated with developing new and improved drugs to combat these serious bacterial and fungal infections. On behalf of the Board, we look forward to working with and guiding Xellia in this valuable area of development.”

- Ends -

For more information, please contact:

Xellia Pharmaceuticals

Carl-Åke Carlsson, CEO

Tel: +45 32 64 55 00

Dr Aleksandar Danilovski, CSO, Vice President Global R&D

Tel: +45 23 21 90 50 / +385 98 321 346

Instinctif Partners (media relations)

Melanie Toyne Sewell / Eileen Paul / Jen Lewis

Tel: +44 (0) 20 7457 2029 / +44 (0)1260 296 500

Email: xellia@instinctif.com

About Xellia

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, USA, Hungary and China, and currently employs over 1,000 people.

Xellia is a leading supplier of vancomycin and colistimethate sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species. Xellia is also developing novel antibiotics effective against MDR Gram-negative bacteria in a development project with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen), supported by a grant from the Research Council of Norway.

Since July 2013, Xellia has been wholly owned by Novo A/S, the holding Company of the Novo Group.

Further information about Xellia can be found at: www.xellia.com.